Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 2Phase EARLY_PHASE1 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 108Carcinoma, Non-Small-Cell Lung 97Multiple Myeloma 81Prostatic Neoplasms 74Colorectal Neoplasms 60Neoplasms 58Leukemia, Myeloid, Acute 56Lymphoma 48Squamous Cell Carcinoma of Head and Neck 43Melanoma 40Lung Neoplasms 40Ovarian Neoplasms 38Neoplasm Metastasis 37Pancreatic Neoplasms 36Lymphoma, Non-Hodgkin 36Carcinoma, Hepatocellular 34Lymphoma, Large B-Cell, Diffuse 33Head and Neck Neoplasms 32Sarcoma 31Carcinoma, Renal Cell 31Urinary Bladder Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Endometrial Neoplasms 29Leukemia, Lymphocytic, Chronic, B-Cell 28Hodgkin Disease 28Triple Negative Breast Neoplasms 27Myelodysplastic Syndromes 27Hematologic Neoplasms 26Recurrence 25Glioma 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Immunoglobulin Light-chain Amyloidosis × 30 days × Clear all
NCT05951049 2026-05-06

A Study of AT-02 in Subjects With Systemic Amyloidosis.

Attralus, Inc.

Phase 2 Active not recruiting
120 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡